Oligomerix
Oligomerix is a privately held, clinical-stage biotechnology company developing oral, disease-modifying small molecule inhibitors of tau self-association for Alzheimer's disease and rare neurodegenerative tauopathies such as PSP, FTD, and ALS.
- Company typePrivate
- Founded2006
- HeadquartersBronx, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Oligomerix does
Oligomerix, Inc. is a privately held clinical-stage biotechnology company founded in 2006 and headquartered at the Albert Einstein College of Medicine campus in the Bronx, New York. The company is singularly focused on developing oral, disease-modifying small molecule therapeutics that inhibit tau protein self-association—the earliest step in the tau aggregation cascade implicated in Alzheimer's disease and related tauopathies. Its lead clinical asset, OLX-07010, is an oral small molecule that has completed Phase 1a testing (May 2026) with a favorable safety profile and is being progressed toward Phase 1b studies in patients; a second-generation series of tau aggregation inhibitors and a companion biomarker program extend the pipeline. Proprietary technology is centered on a screening platform using full-length tau under conditions promoting oligomer formation without aggregation enhancers or intercalating dyes, protected by an issued patent estate spanning composition-of-matter, methods-of-use, and antibody reagent claims in the US and internationally.
Oligomerix serves patients with Alzheimer's disease (addressable population of 6.7 million in the US, projected to reach 12.7 million by 2050) and rare tauopathies including progressive supranuclear palsy (PSP), frontotemporal dementia (FTD), and amyotrophic lateral sclerosis (ALS). The company has no commercialized products and does not generate product revenue; its intended go-to-market is to advance OLX-07010 through early-stage clinical development in-house and then partner with larger pharmaceutical companies for late-stage development, global manufacturing, and commercialization. The June 2026 exclusive worldwide licensing agreement with NanoDetection Technology for a portfolio of nine Tau diagnostic antibodies extends the franchise into companion diagnostics. To date, the company has been funded primarily through non-dilutive NIH/NIA SBIR and related grants (cumulatively over $15 million) and modest equity rounds (Series A $2 million in April 2013, Series B extension $2.7 million in June 2022).
Oligomerix firmographics
Firmographics- Name
- Oligomerix
- Legal name
- Oligomerix, Inc.
- Website
- https://oligomerix.com
- Company type
- Private
- Founded year
- 2006
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Oligomerix is a privately held, clinical-stage biotechnology company developing oral, disease-modifying small molecule inhibitors of tau self-association for Alzheimer's disease and rare neurodegenerative tauopathies such as PSP, FTD, and ALS.
- Ownership category
- akta.pro rank
Oligomerix industry classification
Industry- Product category
- Neurodegenerative Disease Therapeutics
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835)
- akta.pro industry
- Enzyme Replacement & Metabolic Disorder Therapies
Keywords
Where Oligomerix is headquartered
LocationHeadquarters
- HQ city
- Bronx
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Oligomerix business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales
Revenue model
- Drug Development and Commercialization: Pre-revenue biotech company developing disease-modifying oral small molecule therapeutics for Alzheimer's disease and rare neurodegenerative diseases. Revenue will be generated through eventual product sales following regulatory approval.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels3 records
Oligomerix product offering
Product offeringCore offering
Oligomerix is a clinical-stage biotechnology company that discovers and develops oral, disease-modifying small molecule therapeutics that inhibit tau protein self-association at the beginning of the tau aggregation cascade. Its lead candidate OLX-07010 targets Alzheimer's disease and rare tauopathies such as progressive supranuclear palsy (PSP) and frontotemporal dementia (FTD), supported by a proprietary screening platform, a 2nd generation compound series, a companion biomarker program, and a recently licensed portfolio of diagnostic tau antibodies.
Product overview
Oligomerix is a clinical stage biotechnology company pioneering disease-modifying, oral small molecule therapeutics targeting protein aggregation in Alzheimer's disease and rare neurodegenerative diseases. The company's core product is OLX-07010, a small molecule inhibitor of tau self-association currently in Phase 1a clinical trials. The platform includes a 2nd generation series of tau aggregation inhibitors and a companion biomarker program. In June 2026, the company expanded into diagnostics through an exclusive licensing agreement for a portfolio of nine Tau antibodies for neurodegenerative disease diagnostics.
Differentiator
Problem solved
Functional benefit
Products and services
- OLX-07010 Oral, disease-modifying small molecule inhibitor of tau self-association for the treatment of Alzheimer's disease and rare tauopathies including progressive supranuclear palsy (PSP) and frontotemporal dementia (FTD). Currently in Phase 1a clinical development with a completed Phase 1a study in May 2026 showing a favorable safety profile.
- 2nd Generation Tau Aggregation Inhibitor Series Second generation series of small molecule tau aggregation inhibitors in preclinical development alongside the lead compound OLX-07010.
- Companion Biomarker Program Biomarker development program companion to the therapeutic platform, supporting drug development and potentially patient selection for clinical trials.
- Tau Antibody Diagnostic Portfolio Portfolio of nine specialized Tau antibodies for detection of specific forms of aggregated Tau to advance diagnostics for Alzheimer's disease and distinguish it from other neurodegenerative conditions including Frontotemporal Dementia, Progressive Supranuclear Palsy, and Corticobasal Degeneration.
Quantifiable outcome
- Phase 1a clinical trial completed in 2025/2026
- +2 more outcomes
Companies that use Oligomerix
Customer profileSegments2 records
Ideal customer profiles3 records
Oligomerix technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability2 records
Feature4 records
Oligomerix partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered core and minor.
- NanoDetection TechnologycoreExclusive worldwide licensing agreement for a portfolio of nine specialized Tau antibodies designed to advance diagnostics for Alzheimer's disease and related neurodegenerative disorders. The technology enables detection of specific forms of aggregated Tau that may help distinguish Alzheimer's from other conditions including Frontotemporal Dementia, Progressive Supranuclear Palsy, and Corticobasal Degeneration. NanoDetection has integrated the antibodies into its TRACE-Tau platform with clinical validation ongoing through collaborations with UMass Chan Medical School.
- Feinstein Institutes for Medical ResearchminorCollaboration on in vivo Alzheimer's disease treatment data publication.
- Albert Einstein College of MedicineminorThe company relocated to the Albert Einstein College of Medicine campus for research collaboration purposes.
- UMass Chan Medical SchoolminorClinical validation ongoing through collaborations with UMass Chan Medical School for diagnostic antibody technology.
Scale indicators5 records
Recent moves6 records
Expansion highlights5 records
Oligomerix competitors and assessment
Company assessmentEmerging players
- Denali Therapeutics: Clinical-stage biotech developing therapeutics for neurodegeneration and lysosomal storage diseases, including small molecule approaches to tau and other CNS targets. Comparable as a CNS-focused biotech, though broader in scope.
- Sage Therapeutics: Clinical-stage CNS biopharma developing therapeutics for neurological disorders including Alzheimer's agitation. Comparable as a small-cap neuroscience-focused developer, though Sage's focus is broader.
Direct peers
- Prothena Corporation: Clinical-stage biotech developing therapeutics against misfolded proteins including tau and amyloid for Alzheimer's and rare neurodegenerative diseases. Directly comparable in target class, indication focus, and small-molecule/biologic modality mix.
- Cognition Therapeutics: Clinical-stage biotech developing oral small molecule therapeutics for Alzheimer's disease and dementia-related disorders. Comparable in modality (oral small molecule), indication (AD), and clinical-stage positioning.
- AC Immune SA: Swiss clinical-stage biotech developing both therapeutics and diagnostics targeting tau, amyloid, and neuroinflammation for Alzheimer's and related dementias. Closely comparable given shared tau focus and dual therapeutic/diagnostic strategy.
- Anavex Life Sciences: Clinical-stage biotech developing oral small molecule sigma-1 receptor agonists (blarcamesine) for Alzheimer's, Rett syndrome, and other neurodegenerative diseases. Comparable in oral small molecule approach and neurodegenerative indication focus.
- Cassava Sciences: Clinical-stage biotech developing oral small molecule therapeutics (simufilam) for Alzheimer's disease. Comparable as a small-molecule AD therapeutics developer at similar clinical stage.
Broad incumbents
- Biogen: Large biopharmaceutical company with the leading approved disease-modifying Alzheimer's franchise (Leqembi, with Eisai) and a broad neuroscience pipeline. Sets the competitive bar Oligomerix must clear in AD.
- Eisai: Japanese pharmaceutical company co-developing Leqembi with Biogen for Alzheimer's and pursuing additional tau-targeting programs. A likely BD/licensing partner and major competitive incumbent in AD.
- Eli Lilly: Large pharmaceutical company with the approved anti-amyloid Kisunla (donanemab) and a broad neuroscience pipeline including tau and other AD targets. Sets competitive and regulatory benchmarks in AD therapeutics.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
Oligomerix social profiles
Digital presenceOligomerix financial estimates
Financial estimateRevenue estimate
Valuation estimate
Oligomerix leadership team
Management profileNumber of profiles
Profiles14 records
Oligomerix funding detail
Funding detailFunding overview
Funding rounds10 records
Investors6 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Oligomerix M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Oligomerix
What does Oligomerix do?
Oligomerix is a clinical-stage biotechnology company that discovers and develops oral, disease-modifying small molecule therapeutics that inhibit tau protein self-association at the beginning of the tau aggregation cascade. Its lead candidate OLX-07010 targets Alzheimer's disease and rare tauopathies such as progressive supranuclear palsy (PSP) and frontotemporal dementia (FTD), supported by a proprietary screening platform, a 2nd generation compound series, a companion biomarker program, and a recently licensed portfolio of diagnostic tau antibodies.
Is Oligomerix a public or private company?
Oligomerix is a private company. It is classified as venture growth investor backed and is currently operating.
When was Oligomerix founded?
Oligomerix was founded in 2006. It employs 11 to 50 people.
Where is Oligomerix based?
Oligomerix is headquartered in Bronx, United States, in the North America region.
How does Oligomerix make money?
One revenue line is on record: drug Development and Commercialization.
Who are Oligomerix's main competitors?
Emerging players on record are Denali Therapeutics and Sage Therapeutics. Direct peers are Prothena Corporation, Cognition Therapeutics, AC Immune SA, Anavex Life Sciences and Cassava Sciences. Broad incumbents are Biogen, Eisai and Eli Lilly.
Does Oligomerix have an API?
No public API is recorded for Oligomerix.
What industry is Oligomerix in?
Oligomerix's product category is Neurodegenerative Disease Therapeutics. Its primary akta.pro industry code is HLAIAIAB, Enzyme Replacement & Metabolic Disorder Therapies. Its NAICS code is 541714 and its SIC code is 2835.